# Acuta Capital Partners

> Acuta Capital Partners is a VC fund backing Biotechnology and Health Care. See 17 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 17
- Last investment: May 2026
- Lead investor: 6%
- Last updated: Aug 2026

Acuta Capital Partners is a VC fund focused on Biotechnology and Health Care. Acuta Capital Partners

## Contacts

5 contacts available for Acuta Capital Partners. Shizune tracks 1 team members at Acuta Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/acuta-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 14 | 82% |
| Health Care | 7 | 41% |
| Therapeutics | 4 | 24% |
| Medical | 3 | 18% |
| Biopharma | 3 | 18% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 10 | 59% |
| Series B | 2 | 12% |
| Series C | 1 | 6% |
| Funding Round | 1 | 6% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 76% |
| Ireland | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Scott Smith | COO/CCO | 0 | https://shizune.co/investors/profile/scott-smith-4 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Whitehawk Therapeutics | Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $87.5M | Post-IPO Equity | May 13, 2026 |  |
| Sutro Biopharma | Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $110M | Post-IPO Equity | Feb 10, 2026 |  |
| Surrozen | Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system. | $175M | Post-IPO Equity | Mar 24, 2025 |  |
| Whitehawk Therapeutics | Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $100M | Post-IPO Equity | Mar 04, 2025 |  |
| Enliven Therapeutics | Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectivelydevelop precision oncology therapeutics that enhance overall patient well-being.Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado. | $90M | Post-IPO Equity | Mar 19, 2024 |  |
| Ocular Therapeutix | Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic andbiocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma. | $325M | Post-IPO Equity | Feb 22, 2024 |  |
| Tourmaline Bio | Tourmaline Bio is a clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients and prevent immune diseases. | $75M | Post-IPO Equity | Oct 19, 2023 |  |
| BioAtla | BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated AntibodyOptimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers. | $65M | Post-IPO Equity | Nov 04, 2022 |  |
| Whitehawk Therapeutics | Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $72.5M | Post-IPO Equity | Sep 22, 2022 |  |
| Ventyx Biosciences | Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Ventyx’s clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. | $176.6M | Post-IPO Equity | Sep 19, 2022 |  |

10 of 17 investments shown.

## Co-investors
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 8 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 7 deals together
- [KVP Capital](https://shizune.co/investors/profile/kvp-capital) — VC Fund, 6 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 6 deals together
- [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 6 deals together
- [Avoro Capital Advisors](https://shizune.co/investors/profile/avoro-capital-advisors) — VC Fund, 5 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Acuta Capital Partners invest in?

Acuta Capital Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Acuta Capital Partners?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Acuta Capital Partners?

The team at Acuta Capital Partners includes Scott Smith (COO/CCO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co